^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC)
Published date:
08/27/2020
Excerpt:
OS was also prolonged in CCDC6-RET fusion versus KIF5B-RET fusion positive patients (median 113.5 vs. 37.7 months; HR 0.12, 95%CI 0.04-0.38, p=0.009)....In RET rearranged NSCLC, selective RET TKI therapy is associated with improved survival outcomes, especially in CCDC6-RET positive patients.
DOI:
https://doi.org/10.1016/j.jtho.2020.08.011
